Lisata Therapeutics, Inc. (LSTA) Financial Ratios
31 years of historical data (1995–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
30Y Low0.9·High0.9
P/B Ratio
↑
1.92
↑+208% vs avg
5yr avg: 0.62
30Y Low0.2·High53.3
ROE
↓
-75.5%
↑-37% vs avg
5yr avg: -55.3%
30Y Low-442%·High85%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
LSTA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Lisata Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $29M | $16M | $25M | $22M | $13M | $46M | $22M | $26M | $34M | $31M | $19M |
| Enterprise Value | $13M | $201820 | $9M | $-385710 | $-18563600 | $23M | $6M | $13M | $24M | $2M | $11M |
| P/E Ratio → | -1.69 | — | — | — | — | — | — | — | — | 1.37 | — |
| P/S Ratio | 173.02 | 95.05 | 24.82 | — | — | — | — | — | — | — | 0.53 |
| P/B Ratio | 1.92 | 1.11 | 0.85 | 0.46 | 0.20 | 0.51 | 0.68 | 1.26 | 0.92 | 0.63 | 4.56 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
LSTA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.19 | 8.75 | — | — | — | — | — | — | — | 0.30 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
LSTA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Lisata Therapeutics, Inc. earns an operating margin of -10711.2%. Operating margins have compressed from -2240.9% to -10711.2% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -75.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 14.1% | 14.1% | 100.0% | — | — | — | — | — | — | — | 11.8% |
| Operating Margin | -10711.2% | -10711.2% | -2240.9% | — | — | — | — | — | — | — | -88.8% |
| Net Profit Margin | -9756.5% | -9756.5% | -1998.5% | — | — | — | — | — | — | — | -92.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -75.5% | -75.5% | -51.8% | -36.5% | -68.5% | -44.2% | -30.9% | -69.3% | -36.9% | 84.7% | -238.8% |
| ROA | -62.9% | -62.9% | -44.6% | -32.6% | -63.8% | -41.3% | -25.8% | -56.0% | -30.0% | 39.9% | -59.9% |
| ROIC | -229.7% | -229.7% | -86.8% | -64.1% | -84.1% | -51.6% | -120.4% | -87.0% | -52.7% | -238.7% | -295.7% |
| ROCE | -82.7% | -82.7% | -57.8% | -44.8% | -72.4% | -46.5% | -71.3% | -66.8% | -36.5% | -63.9% | -91.5% |
LSTA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $16M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 | 0.05 | — | 0.00 | 1.67 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.09 | -0.55 | -0.47 | -0.48 | -0.26 | -0.49 | -0.64 | -0.27 | -0.58 | -1.95 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | -3397.40 | -73.04 | -15.87 |
Net cash position: cash ($16M) exceeds total debt ($0)
LSTA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Lisata Therapeutics, Inc.'s current ratio of 5.76x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 8.18x to 5.76x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.76 | 5.76 | 6.16 | 8.18 | 11.26 | 21.27 | 10.08 | 4.35 | 7.85 | 6.56 | 1.26 |
| Quick Ratio | 5.76 | 5.76 | 6.16 | 8.18 | 11.26 | 21.27 | 10.08 | 4.35 | 7.85 | 6.02 | 1.08 |
| Cash Ratio | 5.20 | 5.20 | 5.57 | 7.67 | 10.85 | 21.00 | 9.86 | 4.21 | 7.66 | 5.91 | 0.75 |
| Asset Turnover | — | 0.01 | 0.03 | — | — | — | — | — | — | — | 0.68 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | 0.07 | 0.13 |
| Days Sales Outstanding | — | 1502.94 | 328.50 | — | — | — | — | — | — | — | 1.44 |
LSTA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Lisata Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | 80.9% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | 73.0% | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 80.9% |
| Shares Outstanding | — | $9M | $8M | $8M | $5M | $4M | $1M | $688333 | $645933 | $597933 | $436550 |
Peer Comparison
Compare LSTA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 LSTAYou | $29M | -1.7 | — | — | 14.1% | -10711.2% | -75.5% | -229.7% | — |
 ADCT | $478M | -3.4 | — | — | 90.6% | -133.2% | — | — | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 TPVG | $243M | 4.9 | 9.1 | — | 83.5% | 77.9% | 14.1% | 7.2% | 6.2 |
 CRVS | $1B | -27.5 | — | — | — | — | -32.6% | -78.1% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 MGNX | $186M | -2.5 | — | — | — | -48.7% | -86.9% | -1879.3% | — |
 CRL | $9B | -62.5 | 13.0 | 17.3 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See LSTA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LSTA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LSTA vs ADCT
Side-by-side business, growth, and profitability comparison vs ADC Therapeutics S.A..
Start ComparisonLSTA — Frequently Asked Questions
Quick answers to the most common questions about buying LSTA stock.
What is Lisata Therapeutics, Inc.'s P/E ratio?
Lisata Therapeutics, Inc.'s current P/E ratio is -1.7x. The historical average is 1.4x.
What is Lisata Therapeutics, Inc.'s ROE?
Lisata Therapeutics, Inc.'s return on equity (ROE) is -75.5%. The historical average is -90.3%.
Is LSTA stock overvalued?
Based on historical data, Lisata Therapeutics, Inc. is trading at a P/E of -1.7x. Compare with industry peers and growth rates for a complete picture.
What are Lisata Therapeutics, Inc.'s profit margins?
Lisata Therapeutics, Inc. has 14.1% gross margin and -10711.2% operating margin.